Cagrilintide Dosage: Starting Dose, Chart, and Schedule

Cagrilintide is an investigational amylin analog that is not FDA-approved for human use. In clinical trials, the typical cagrilintide starting dose has been 0.16 mg to 0.3 mg injected once weekly, followed by gradual titration up to 2.4 mg or occasionally 4.5 mg per week. Because cagrilintide remains an experimental peptide, no official dosing guidelines exist for the general public, and anyone considering it should consult a licensed healthcare professional.

What Is Cagrilintide and Why Does Dosage Matter?

Cagrilintide is a long-acting peptide that mimics amylin, a hormone that helps regulate appetite and gastric emptying. Researchers are studying it both as a standalone treatment and in combination with semaglutide, a combination often called CagriSema. For a side-by-side view of the combination, many researchers consult a cagrisema dosage chart.

Dosage matters because cagrilintide can cause gastrointestinal side effects such as nausea, vomiting, and diarrhea, especially when the dose is increased too quickly. Clinical trials have used stepwise titration to improve tolerability. There is no FDA-approved cagrilintide dose, so any use outside a clinical trial is experimental and carries unknown risks.

Cagrilintide Dosage Chart: Clinical Trial Ranges

The following table summarizes weekly cagrilintide doses studied in clinical trials. This cagrilintide dosage chart reflects research protocols, not official medical recommendations.

Study Phase	Weekly Dose	Typical Duration	Notes
Starting dose	0.16 mg – 0.3 mg	2–4 weeks	Lowest step to assess tolerability
Titration step 1	0.6 mg	2–4 weeks	Gradual increase if tolerated
Titration step 2	1.2 mg	2–4 weeks	Mid-range dose
Titration step 3	2.4 mg	4+ weeks	Common target in trials
Maximum studied	4.5 mg	Varies	Highest dose in some trials

These numbers reflect investigational use only. The cagrilintide max dose in published trials has been 4.5 mg per week, but 2.4 mg is more common when combined with semaglutide. Individual responses vary, and a healthcare professional should supervise any clinical use.

Cagrilintide Starting Dose and Titration Schedule

If you are asking what is the starting dose of cagrilintide, the research answer is typically 0.16 mg to 0.3 mg once weekly. The cagrilintide starting dose is intentionally low to let the body adjust. After two to four weeks, the dose is usually increased to 0.6 mg, then to 1.2 mg, and eventually to 2.4 mg.

A standard cagrilintide dosing schedule follows this pattern:

1. Weeks 1–4: 0.16 mg to 0.3 mg once weekly.
2. Weeks 5–8: 0.6 mg once weekly.
3. Weeks 9–12: 1.2 mg once weekly.
4. Week 13 and beyond: 2.4 mg once weekly, or as tolerated.

Some trials have used a faster or slower titration. The cagrilintide dosage schedule is not standardized because the drug is not approved. Never change a dose without medical guidance.

Cagrilintide 5 mg and 10 mg Vials: Dosing in Units vs Milligrams

Research peptides are often sold as lyophilized powder in 5 mg or 10 mg vials. To dose cagrilintide, you must reconstitute the powder with bacteriostatic water and calculate the concentration. A peptide calculator can help you convert milligrams to units on an insulin syringe.

For example, if you add 2 mL of water to a 5 mg vial, the concentration is 2.5 mg/mL. That means:

• 0.5 mg = 0.2 mL = 20 units on a U-100 syringe
• 1.2 mg = 0.48 mL = 48 units
• 2.4 mg = 0.96 mL = 96 units

If you add 2 mL to a 10 mg vial, the concentration is 5 mg/mL, so 2.4 mg = 0.48 mL = 48 units. These calculations are for educational purposes only. A cagrilintide dosing chart in units depends entirely on your vial size and reconstitution volume. Always double-check with a peptide calculator and a pharmacist if you are in a supervised research setting.

Many people searching for cagrilintide 5mg dosage or cagrilintide 10mg dosage are really trying to figure out how much cagrilintide to take. The honest answer is that no safe, approved dose exists for self-administration. Cagrilintide is not approved for any human use, so self-dosing is risky.

Cagrilintide Dosage for Weight Loss: What Research Shows

Clinical trials have studied cagrilintide dosage for weight loss in people with obesity or type 2 diabetes. In combination with semaglutide (CagriSema), participants have lost significant weight over 68 weeks. However, cagrilintide is not a cure for obesity, and weight loss varies by individual.

The most common side effects are gastrointestinal. These include nausea, vomiting, diarrhea, and constipation. Starting at a low dose and titrating slowly can reduce these effects. Anyone with a history of pancreatitis, gallbladder disease, or gastroparesis should avoid cagrilintide unless a doctor says otherwise.

If you are exploring other research peptides, you may also see protocols like aod-9604 5mg dosage or ss-31 peptide injection dosage discussed in fitness and longevity circles. Those are separate compounds with their own risks and no FDA approval.

Cagrilintide Max Dose and Safety Considerations

The highest cagrilintide dose studied in clinical trials is 4.5 mg once weekly. The cagrilintide max dose is not established for real-world use because the drug has not received regulatory approval. Doses above 4.5 mg have not been well studied in humans.

Important safety points:

• Cagrilintide is not FDA-approved for weight loss or any other human use.
• Common side effects include nausea, vomiting, diarrhea, and injection-site reactions.
• Rare but serious risks may include pancreatitis and gallbladder problems.
• Cagrilintide should not be used during pregnancy or breastfeeding.
• Self-dosing with research-grade peptides is dangerous because purity and potency are not guaranteed.

Always talk to a healthcare professional before using any peptide. This article is for information only and is not medical advice.

For comparison, growth hormone secretagogues such as sermorelin ipamorelin cjc1295 dosage follow completely different dosing rules and are not approved for over-the-counter use either.

COMMON QUESTIONS

Frequently Asked Questions

What is the starting dose of cagrilintide?

In clinical trials, the cagrilintide starting dose is typically 0.16 mg to 0.3 mg injected once weekly. After two to four weeks, the dose is gradually increased. Cagrilintide is not FDA-approved, so there is no official starting dose for the public.

What is the maximum dose of cagrilintide?

The highest cagrilintide dose studied in clinical trials is 4.5 mg once weekly. In the CagriSema combination, 2.4 mg cagrilintide with 2.4 mg semaglutide is more common. Doses above 4.5 mg have not been well studied in humans.

How do I convert cagrilintide mg to units?

Converting cagrilintide mg to units requires knowing your vial size and how much water you added. For a 5 mg vial reconstituted with 2 mL of water, the concentration is 2.5 mg/mL, so 2.4 mg equals 0.96 mL or 96 units on a U-100 syringe. Always use a peptide calculator and verify with a healthcare professional.